(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 5.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.72%.
Catalyst Pharmaceuticals's revenue in 2025 is $578,196,000.On average, 10 Wall Street analysts forecast CPRX's revenue for 2025 to be $72,448,248,269, with the lowest CPRX revenue forecast at $68,962,452,974, and the highest CPRX revenue forecast at $75,630,449,969. On average, 10 Wall Street analysts forecast CPRX's revenue for 2026 to be $77,669,566,469, with the lowest CPRX revenue forecast at $71,732,898,177, and the highest CPRX revenue forecast at $81,779,756,690.
In 2027, CPRX is forecast to generate $83,516,508,719 in revenue, with the lowest revenue forecast at $76,693,642,116 and the highest revenue forecast at $92,818,518,167.